Primary resistance occurs when tumor cells are intrinsically incapable of responding to the immune checkpoint blockade due to defects in antigen presentation, such as the loss of β2-microglobulin or mutations in JAK1/2. This evidence concerns the gene JAK1 and neoplasm.